Sign in Subscribe
Pharmaceutical industry

Norak Biosciences Secures Broad European Patent for Transfluor(R) Technology

Strategic Insights

— 1 min read

Norak Biosciences, Inc. has announced a significant milestone in the expansion of its intellectual property portfolio, with the broad issuance of a European patent covering compositions of matter and methods that protect its patented Transfluor(R) technology. This patent, EP1015608, claims compositions and cells including a conjugate of a beta-arrestin, including variants, and any detectable molecule, such as a fluorescent protein or enzyme moiety. This achievement represents a major breakthrough for Norak, solidifying its position as a leading player in the discovery and development of drugs that regulate G protein-coupled receptors.

Key Takeaways:

  • The newly issued European patent, EP1015608, expands Norak's intellectual property portfolio and secures exclusive rights to its Transfluor(R) technology in Europe.
  • The patent claims compositions and cells including a conjugate of a beta-arrestin, including variants, and any detectable molecule, such as a fluorescent protein or enzyme moiety.
  • The patent was internationally filed in June 1998 and published in December 1998, and has been translated throughout EPO member countries.
  • Norak's Transfluor(R) technology is a patented, universal GPCR drug discovery technology designed to be the most accurate method for discovering ligands for GPCR targets, whether known or orphan.
  • The technology was exclusively licensed in 1999 by Norak from Duke University Medical Center and represents the combined research into GPCR signaling pathways over several decades by Norak's scientific founders, Drs. Marc Caron, Robert Lefkowitz, and Larry Barak.
  • Norak Biosciences, Inc. is a private biotechnology company headquartered in Research Triangle Park, NC, utilizing its proprietary Transfluor(R) technology to become a worldwide leader in the discovery and development of drugs.
  • The company has successfully licensed its technology to parties interested in its diagnostic and therapeutic applications.

Statistics:

  • The patent was internationally filed in June 1998.
  • The patent was published in December 1998.
  • The patent was translated throughout EPO member countries.
  • The Transfluor(R) technology was exclusively licensed in 1999 by Norak from Duke University Medical Center.
  • 3 scientific founders, Drs. Marc Caron, Robert Lefkowitz, and Larry Barak, contributed to the development of the technology through their research into GPCR signaling pathways.
  • Norak Biosciences, Inc. has a presence in Research Triangle Park, NC.

Sources:

  • Norak Biosciences, Inc. (press release, March 30)
  • http://www.norakbio.com/

Read more